Exclusive: Mercor’s Fast Growth Relies on Biggest AI Companies, Documents Show Save 25% to unlock this story

Sign in
Subscribe

    Data Tools

    • About Pro
    • Enterprise Software Startup Takeover List 2026
    • The Next GPs 2026
    • The Executives Leading the Data Center Race
    • The Next GPs 2025
    • The Rising Stars of AI Research
    • Leaders of the AI Shopping Revolution
    • Enterprise Software Startup Takeover List 2025
    • Org Charts
    • The Information 50 2025
    • Generative AI Takeover List
    • Generative AI Database
    • AI Chip Database
    • AI Data Center Database
    • Tech IPO Tracker
    • Tech Sentiment Tracker
    • Gigafactory Database

    Special Projects

    • The Information 50 Database
    • VC Diversity Index
    • Enterprise Tech Powerlist
  • Org Charts
  • Deep Research
  • Tech
  • Finance
  • Weekend
  • Charts
  • Events
  • TITV
    • Directory

      Search, find and engage with others who are serious about tech and business.

    • Forum

      Follow and be a part of discussions about tech, finance and media.

    • Brand Partnerships

      Premium advertising opportunities for brands

    • Group Subscriptions

      Team access to our exclusive tech news

    • Newsletters

      Journalists who break and shape the news, in your inbox

    • Video

      Catch up on conversations with global leaders in tech, media and finance

    • Partner Content

      Explore our recent partner collaborations

      XFacebookLinkedInThreadsInstagram
    • Help & Support
    • RSS Feed
    • Careers
    Sign in
  • About Pro
  • Enterprise Software Startup Takeover List 2026
  • The Next GPs 2026
  • The Executives Leading the Data Center Race
  • The Next GPs 2025
  • The Rising Stars of AI Research
  • Leaders of the AI Shopping Revolution
  • Enterprise Software Startup Takeover List 2025
  • Org Charts
  • The Information 50 2025
  • Generative AI Takeover List
  • Generative AI Database
  • AI Chip Database
  • AI Data Center Database
  • Tech IPO Tracker
  • Tech Sentiment Tracker
  • Gigafactory Database

SPECIAL PROJECTS

  • The Information 50 Database
  • VC Diversity Index
  • Enterprise Tech Powerlist
Deep Research
TITV
Tech
Finance
Weekend
Charts
Events
Newsletters
  • Directory

    Search, find and engage with others who are serious about tech and business.

  • Forum

    Follow and be a part of discussions about tech, finance and media.

  • Brand Partnerships

    Premium advertising opportunities for brands

  • Group Subscriptions

    Team access to our exclusive tech news

  • Newsletters

    Journalists who break and shape the news, in your inbox

  • Video

    Catch up on conversations with global leaders in tech, media and finance

  • Partner Content

    Explore our recent partner collaborations

Subscribe
  • Sign in
  • Search
  • Opinion
  • Venture Capital
  • Artificial Intelligence
  • Startups
  • Market Research
    XFacebookLinkedInThreadsInstagram
  • Help & Support
  • RSS Feed
  • Careers

Scale confidently.Scale confidently.

Learn more
Featured Partner
PwC logo
Exclusive

Bolt’s Breslow Teams With Psychedelics Founder on Crypto Pharma Startup

Love co-founders Ashwath Rajan, Ryan Breslow and JR Rahn. Photo by Julian Buitrago
By
Kate Clark
[email protected]Profile and archive

Bolt co-founder Ryan Breslow, who stepped down as the e-commerce software startup’s CEO after publishing a Twitter rant aimed at powerful Silicon Valley institutions, is taking another stab at startup leadership. This time he’s planning to develop drugs initially based on nutraceuticals, food-derived substances that have health benefits, to treat sleep and pain problems.

Breslow has founded the startup, Love Health, with JR Rahn, co-founder of MindMed, a publicly traded developer of psychedelic-based medicines, and Ashwath Rajan, who co-founded Stockwell AI, an ill-fated vending-machine startup formerly known as Bodega.

The Miami-based company plans to perform clinical trials to seek Food and Drug Administration approval for its drugs, which will focus on “solutions to the opioid crisis,” said Rahn, who is CEO, in an interview with The Information. Love will eventually expand to pharmaceuticals and has no immediate plans to use psychedelics, he said. In the future, the company may issue a cryptocurrency token to participants in its clinical trials.

Recommended